|
Peter Kleinhenz is a Managing Director of CID Capital. He has been actively involved in technology-based businesses as an entrepreneur, consultant, and investor for over twenty-five years and has provided leadership for new venture formation in the life sciences sector for over 20 years. Peter leads the firm's investments in health care technology. Peter is a director or observer for the following CID investments: Axiomed Spine Corporation, EKOS Corporation, Renal Solutions Inc., Celleration, Inc and RedPath, Inc.
Prior to joining CID Capital in 2001, Peter served as Vice President of Commercialization for Battelle Memorial Institute and as a consultant to The Cleveland Clinic Foundation, Battelle, and a variety of life science start-ups, assisting in developing business plans and raising seed and venture capital. He was CEO and principal owner of Progenics, a product development and pilot manufacturing company for medical products and industrial controls, which he sold in 1997. Prior to this he served in a variety of senior executive positions including CFO, Vice President of Manufacturing, and Vice President of Strategic Planning and Business Development at Neoprobe Corporation, a biotech and medical device company focused on cancer diagnostics and therapeutics. Peter received an MBA from Case Western Reserve University, a bachelor's degree in history from Loyola University of Chicago, and is a Certified Public Accountant licensed in Ohio. | 